Arcturus Therapeutics Holdings

ARCT · NASDAQ

$10.98+$0.56 (+5.37%)TodayMarket closed · Oct 20, 7:48 PM ET

Prev close $10.42

ARCT analyst rating

BuyConsensus of 10 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy8
Hold2
Underperform0
Sell0

12-month price target · 12 analysts

Average $23.66 (+115.5% upside)

Low: $9.09
Now: $10.98
High: $43.05

Upgrades and downgrades

The latest rating actions, newest first

ARCT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Leerink Partners	Oct 9, 2026	Maintains	Outperform	$13.00 → $19.00	0%
Citigroup	Sep 24, 2026	Upgrade	Neutral → Buy	$8.00 → $20.00	42%
BTIG	Sep 24, 2026	Maintains	Buy	$23.00 → $20.00	30%
Freedom Broker	Jul 2, 2026	Initiates	Buy	$27.00	45%
B. Riley Securities	Mar 18, 2026	Initiates	Neutral → Buy	$22.00	47%
Citigroup	Mar 5, 2026	Maintains	Buy	$66.00 → $21.00	41%
Citigroup	Mar 4, 2026	Maintains	Neutral	$7.00 → $8.00	42%
Piper Sandler	Mar 4, 2026	Maintains	Overweight	$72.00 → $25.00	37%
Citigroup	Jan 6, 2026	Maintains	Neutral	$9.00 → $7.00	42%
Citigroup	Nov 13, 2025	Maintains	Neutral	$12.00 → $9.00	42%

The case for and against

Updated Oct 18, 2026

Bull case

Arcturus Therapeutics is attractive because its approved Kostaive vaccine validates the self-amplifying mRNA platform and de-risks the broader LUNAR delivery technology, potentially opening additional partnership and business-development opportunities. The company’s internal rare-disease programs also appear more compelling after early ARCT-810 data showed all participants benefited, with glutamine falling in every participant and some moving into the normal range while ammonia stayed within normal limits, supporting biological activity despite prior confounders. In cystic fibrosis, ARCT-032’s Phase 3 go/no-go decision guided for Q4 2026, expanded enrollment across the U.S., Israel, and Turkey, and the 12-week study design should provide substantially more meaningful exposure than the prior 4-week study.

Bear case

Arcturus Therapeutics is facing a negative fundamental setup because its core opportunity in OTCD remains highly uncertain despite clinical progress, with ARCT-810 still carrying only a 35% PoS and a 2028 market entry assumption, while competition from gene-agnostic UCD approaches could pressure its long-term addressable market. The company’s own disclosures highlight greater-than-expected operating expenses and cash burn, raising the risk of equity issuances at less attractive valuations, especially given the small revenue base and the need for strong pricing power in rare diseases. Even where efficacy signals are encouraging, development delays, regulatory uncertainty, safety concerns, and the possibility that clinical results fail to translate from preclinical data all support a cautious outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.